OBTAIN A: Outcome Benefits of Tranexamic Acid in Hip Arthroplasty. A Randomized Double-Blinded Controlled Trial
| Autor: | Andrew Fraval, Lena Fiddelaers, Peter Effeney, Belinda J. Smith, Ben Towell, Phong Tran |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Arthroplasty Replacement Hip medicine.medical_treatment Blood Loss Surgical Timed Up and Go test law.invention 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial Blood loss law medicine Humans Blood Transfusion Orthopedics and Sports Medicine Postoperative Period 030212 general & internal medicine Saline Aged Pain Measurement Aged 80 and over 030222 orthopedics business.industry Incidence (epidemiology) Perioperative Length of Stay Middle Aged Antifibrinolytic Agents Surgery Treatment Outcome Tranexamic Acid Anesthesia Female Anterior approach business Tranexamic acid medicine.drug |
| Zdroj: | The Journal of Arthroplasty. 32:1516-1519 |
| ISSN: | 0883-5403 |
| DOI: | 10.1016/j.arth.2016.11.045 |
| Popis: | We examined whether the blood conserving effect of tranexamic acid (TXA) in total hip arthroplasty using the direct anterior approach, translates to an effect on functional outcomes in the perioperative period.We conducted a single-center, randomized, double-blinded, placebo-controlled trial. One hundred one patients were randomized to receive either TXA or an equivalent volume of normal saline. The primary outcome measure was thigh swelling. Secondary outcome measures included, visual analogue pain score, timed up and go test, a 10 meter walk test, and length of stay. Blood loss and the incidence of blood transfusions were also recorded.There were no statistically significant differences between the primary outcome of thigh swelling or the secondary outcome measures of postoperative pain nor mobility. There was a significant reduction in length of stay for those that received TXA 3.58 days (0.84) compared with the control group 4.27 days (0.98) (P.001). There was significantly less intraoperative blood loss observed in the TXA group (0.460L SD 0.228) compared with the control group (0.687L SD 0.283L) (P.001). The estimated blood loss was also significantly less in the TXA group (1.084L SD 0.440) compared with the control group (1.394 L SD 0.426).TXA is an effective agent in reducing blood loss in total hip arthroplasty using the anterior approach. The blood conserving effect of TXA was not associated with improved postoperative recovery across the measures of pain and mobility. Administration of TXA may have a positive effect on reducing the duration of inpatient stays. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect